Combination of an ACE Inhibitor and Indapamide Improves Blood Pressure Control, but Attenuates the Beneficial Effects of ACE Inhibition on Plasma Adiponectin in Patients With Essential Hypertension

• Huang Shao-Sung

  Division of Cardiology, Department of Internal Medicine, Taipei Veterans General Hospital Cardiovascular Research Center, National Yang-Ming University

• Wu Tao-Cheng

  Division of Cardiology, Department of Internal Medicine, Taipei Veterans General Hospital Cardiovascular Research Center, National Yang-Ming University

• Lin Shing-Jong

  Division of Cardiology, Department of Internal Medicine, Taipei Veterans General Hospital Department of Medical Education and Research, Taipei Veterans General Hospital Cardiovascular Research Center, National Yang-Ming University Institute of Clinical Medicine, National Yang-Ming University

• Chen Jaw-Wen

  Division of Cardiology, Department of Internal Medicine, Taipei Veterans General Hospital Department of Medical Education and Research, Taipei Veterans General Hospital Cardiovascular Research Center, National Yang-Ming University Institute of Pharmacology, National Yang-Ming University

抄録

Background: Antihypertensive agents differentially influence the plasma adiponectin concentration and the effects of fixed-dose combination regimens remain unclear. The influence of a combination of an angiotensin-converting enzyme inhibitor (ACEI) and a thiazide-type diuretic or an ACEI alone on plasma adiponectin concentrations in patients with essential hypertension was evaluated in the present study. Methods and Results: After a 2-week placebo run-in phase, 30 patients with essential hypertension were randomized to receive preterax (2 mg perindopril/0.625 mg indapamide) or cilazapril (2.5 mg) once daily for 12 weeks. Plasma adiponectin and insulin concentrations were measured before and after treatment. Insulin resistance was measured by homeostasis assessment index (HOMA-IR). Treatment with preterax (P=0.003) and cilazapril (P=0.031) significantly reduced systolic blood pressure (BP), but only preterax reduced diastolic BP (P=0.024). Cilazapril treatment significantly increased the plasma adiponectin concentration (P=0.025) and reduced plasma triglycerides (P=0.041), whereas preterax treatment increased the plasma insulin concentration (P=0.041) and tended to increase HOMA-IR. Conclusions: The combination of an ACEI and indapamide improved BP control, but attenuated the beneficial effects of ACE inhibition on plasma adiponectin in patients with essential hypertension. Such a combination may be best reserved for improved BP control rather than for metabolic protection in clinical hypertension. (Circ J 2009; 73: 2282-2287)<br>

収録刊行物

• Circulation Journal

  Circulation Journal 73 (12), 2282-2287, 2009

  一般社団法人 日本循環器学会

キーワード

• Adiponectin
• Combination therapy
• Hypertension
• Insulin resistance
• Thiazides

詳細情報

• CRID: 1390001205102470784
• NII論文ID: 10025938377
• NII書誌ID: AA11591968
• DOI: 10.1253/circj.cj-09-0387
• ISSN: 13474820
• ISSN: 13469843
• Web Site: http://www.jstage.jst.go.jp/article/circj/73/12/73_CJ-09-0387/_pdf
• Web Site: https://search.jamas.or.jp/link/ui/2010113123
• 本文言語コード: en
• データソース種別:
  • JaLC
  • Crossref
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可